Drug Profile
Research programme: Nuclear receptor modulators - Karo Pharma
Alternative Names: Nuclear receptor subfamily 4 group A member 1 modulators; Nuclear receptor subfamily 4 group A member 2 modulators; Nur77 modulators; NURR1 modulatorsLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Karo Bio
- Developer Karo Pharma AB
- Class
- Mechanism of Action Nuclear receptor subfamily 4 group A member 1 modulators; Nuclear receptor subfamily 4 group A member 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Autoimmune-disorders in Sweden
- 07 May 2013 Early research is ongoing in Sweden
- 01 May 2012 Early research in Autoimmune disorders in Sweden (unspecified route)